The American Journal of Managed Care

Do Targeted NGS Panels Include NSCLC Guideline-Recommended Biomarkers?

This study evaluates inclusion of National Comprehensive Cancer Network (NCCN) guideline recommended biomarkers for metastatic non–small cell lung cancer (NSCLC) in commercially available targeted ...
Medscape

The New Reflex: Why IHC and RNA Testing Must Join NGS for Lung Cancer

Hello. This is Mark Kris, from Sloan Kettering, continuing my discussion about the increasing precision of lung cancer therapies and the need for additional testing beyond our routine next-generation ...
ascopubs.org

Real-World Association Between Up-Front Next-Generation Sequencing and Overall Survival in Advanced Non–Small Cell Lung Cancer in the United States

Longitudinal Clinical, Physiological, and Molecular Profiling of Female Patients With Metastatic Cancer: Protocol and Feasibility of a Multicenter High-Definition Oncology Study This retrospective ...
RAPS

FDA Discusses How to Regulate NGS Tests for Cancer Diagnoses

The US Food and Drug Administration (FDA) is seeking input on how to regulate next-generation sequencing (NGS) tests that can scan a tumor's genes to guide cancer treatments. At a public workshop at ...
ascopubs.org

Comprehensive profiling of EGFR PACC mutations and their co-mutation landscape in Chinese patients with non–small cell lung cancer: A large-scale NGS study of 2,360 cases.

Five-year outcomes of osimertinib-based treatment in a phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin plus pemetrexed as a ...